CliffBio
small molecule

GRISEOFULVIN

GRISEOFULVIN, MICROSIZE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameGRISEOFULVIN
Active ingredientGRISEOFULVIN, MICROSIZE
Strength125MG/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2007
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

GRISEOFULVIN patent cliff — loss of exclusivity — | CliffBio